Liquidia Analysts Boost Their Forecasts After Q4 Earnings

Benzinga

03/07

Liquidia Corp (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.

The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”

Liquidia shares gained 4.5% to trade at $36.08 on Friday.

These analysts made changes to their price targets on Guidewire Software following earnings announcement.

HC Wainwright & Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.
Wells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.

Considering buying LQDA stock? Here’s what analysts think:

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2617690631"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617690631\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617690631?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-07 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617690631","market":"hk","top_or_hot":-1,"title":"Liquidia Analysts Boost Their Forecasts After Q4 Earnings","media":"Benzinga","content":"<html><body><p><strong>Liquidia Corp</strong> (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.</p>\n<p>The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.</p>\n<p>Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”</p>\n<p>Liquidia shares gained 4.5% to trade at $36.08 on Friday.</p>\n<p>These analysts made changes to their price targets on <a href=\"https://laohu8.com/S/GWRE\">Guidewire Software</a> following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.</li>\n</ul>\n<p><strong>Considering buying LQDA stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"503\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141.png 1235w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Analysts Boost Their Forecasts After Q4 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Analysts Boost Their Forecasts After Q4 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-03-07 00:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Liquidia Corp</strong> (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.</p>\n<p>The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.</p>\n<p>Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”</p>\n<p>Liquidia shares gained 4.5% to trade at $36.08 on Friday.</p>\n<p>These analysts made changes to their price targets on <a href=\"https://laohu8.com/S/GWRE\">Guidewire Software</a> following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.</li>\n</ul>\n<p><strong>Considering buying LQDA stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"503\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141.png 1235w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51101305/liquidia-analysts-boost-their-forecasts-after-q4-earnings","article_id":"2617690631","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617690631","pubTimestamp":1772813851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Liquidia Corp (LQDA) reported mixed Q4 results, with earnings missing estimates but sales beating expectations. Analysts have mixed opinions on stock.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4007":"制药"},"translate_title":"Liquidia分析师在第四季度财报公布后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"Liquidia Corp (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.\nThe company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.\nDr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”\nLiquidia shares gained 4.5% to trade at $36.08 on Friday.\nThese analysts made changes to their price targets on Guidewire Software following earnings announcement.\n\nHC Wainwright & Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.\nWells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.\n\nConsidering buying LQDA stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}